354 related articles for article (PubMed ID: 23863460)
1. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.
Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC
Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460
[TBL] [Abstract][Full Text] [Related]
2. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.
Rhodes SD; Wu X; He Y; Chen S; Yang H; Staser KW; Wang J; Zhang P; Jiang C; Yokota H; Dong R; Peng X; Yang X; Murthy S; Azhar M; Mohammad KS; Xu M; Guise TA; Yang FC
J Bone Miner Res; 2013 Dec; 28(12):2476-89. PubMed ID: 23703870
[TBL] [Abstract][Full Text] [Related]
3. Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.
de la Croix Ndong J; Stevens DM; Vignaux G; Uppuganti S; Perrien DS; Yang X; Nyman JS; Harth E; Elefteriou F
J Bone Miner Res; 2015 Jan; 30(1):55-63. PubMed ID: 25043591
[TBL] [Abstract][Full Text] [Related]
4. A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells.
El-Hoss J; Sullivan K; Cheng T; Yu NY; Bobyn JD; Peacock L; Mikulec K; Baldock P; Alexander IE; Schindeler A; Little DG
J Bone Miner Res; 2012 Jan; 27(1):68-78. PubMed ID: 21956219
[TBL] [Abstract][Full Text] [Related]
5. Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model.
Li H; Liu Y; Zhang Q; Jing Y; Chen S; Song Z; Yan J; Li Y; Wu X; Zhang X; Zhang Y; Case J; Yu M; Ingram DA; Yang FC
Pediatr Res; 2009 Jun; 65(6):613-8. PubMed ID: 19247213
[TBL] [Abstract][Full Text] [Related]
6. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions.
Yang FC; Chen S; Robling AG; Yu X; Nebesio TD; Yan J; Morgan T; Li X; Yuan J; Hock J; Ingram DA; Clapp DW
J Clin Invest; 2006 Nov; 116(11):2880-91. PubMed ID: 17053831
[TBL] [Abstract][Full Text] [Related]
7. Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.
Paria N; Cho TJ; Choi IH; Kamiya N; Kayembe K; Mao R; Margraf RL; Obermosser G; Oxendine I; Sant DW; Song MH; Stevenson DA; Viskochil DH; Wise CA; Kim HK; Rios JJ
J Bone Miner Res; 2014 Dec; 29(12):2636-42. PubMed ID: 24932921
[TBL] [Abstract][Full Text] [Related]
8. Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.
Stansfield BK; Bessler WK; Mali R; Mund JA; Downing BD; Kapur R; Ingram DA
Am J Pathol; 2014 Jan; 184(1):79-85. PubMed ID: 24211110
[TBL] [Abstract][Full Text] [Related]
9. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I.
Wang W; Nyman JS; Ono K; Stevenson DA; Yang X; Elefteriou F
Hum Mol Genet; 2011 Oct; 20(20):3910-24. PubMed ID: 21757497
[TBL] [Abstract][Full Text] [Related]
10. JNK inhibitors increase osteogenesis in Nf1-deficient cells.
Sullivan K; El-Hoss J; Little DG; Schindeler A
Bone; 2011 Dec; 49(6):1311-6. PubMed ID: 21964323
[TBL] [Abstract][Full Text] [Related]
11. A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
El-Hoss J; Cheng T; Carpenter EC; Sullivan K; Deo N; Mikulec K; Little DG; Schindeler A
J Bone Joint Surg Am; 2014 Jul; 96(14):e117. PubMed ID: 25031379
[TBL] [Abstract][Full Text] [Related]
12. β-Catenin modulation in neurofibromatosis type 1 bone repair: therapeutic implications.
Ghadakzadeh S; Kannu P; Whetstone H; Howard A; Alman BA
FASEB J; 2016 Sep; 30(9):3227-37. PubMed ID: 27306335
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1.
Rhodes SD; Yang FC
Curr Osteoporos Rep; 2016 Feb; 14(1):10-5. PubMed ID: 26932441
[TBL] [Abstract][Full Text] [Related]
14. Congenital pseudarthrosis of neurofibromatosis type 1: impaired osteoblast differentiation and function and altered NF1 gene expression.
Leskelä HV; Kuorilehto T; Risteli J; Koivunen J; Nissinen M; Peltonen S; Kinnunen P; Messiaen L; Lehenkari P; Peltonen J
Bone; 2009 Feb; 44(2):243-50. PubMed ID: 19061981
[TBL] [Abstract][Full Text] [Related]
15. c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions.
He Y; Rhodes SD; Chen S; Wu X; Yuan J; Yang X; Jiang L; Li X; Takahashi N; Xu M; Mohammad KS; Guise TA; Yang FC
PLoS One; 2012; 7(11):e46900. PubMed ID: 23144792
[TBL] [Abstract][Full Text] [Related]
16. NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response.
Xu J; Ismat FA; Wang T; Yang J; Epstein JA
Circulation; 2007 Nov; 116(19):2148-56. PubMed ID: 17967772
[TBL] [Abstract][Full Text] [Related]
17. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells.
McDaniel AS; Allen JD; Park SJ; Jaffer ZM; Michels EG; Burgin SJ; Chen S; Bessler WK; Hofmann C; Ingram DA; Chernoff J; Clapp DW
Blood; 2008 Dec; 112(12):4646-54. PubMed ID: 18768391
[TBL] [Abstract][Full Text] [Related]
18. Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1.
Yan J; Chen S; Zhang Y; Li X; Li Y; Wu X; Yuan J; Robling AG; Kapur R; Chan RJ; Yang FC
Hum Mol Genet; 2008 Apr; 17(7):936-48. PubMed ID: 18089636
[TBL] [Abstract][Full Text] [Related]
19. Hyperactive RAS/PI3-K/MAPK Signaling Cascade in Migration and Adhesion of Nf1 Haploinsufficient Mesenchymal Stem/Progenitor Cells.
Zhou Y; He Y; Sharma R; Xing W; Estwick SA; Wu X; Rhodes SD; Xu M; Yang FC
Int J Mol Sci; 2015 Jun; 16(6):12345-59. PubMed ID: 26039236
[TBL] [Abstract][Full Text] [Related]
20. Models of tibial fracture healing in normal and Nf1-deficient mice.
Schindeler A; Morse A; Harry L; Godfrey C; Mikulec K; McDonald M; Gasser JA; Little DG
J Orthop Res; 2008 Aug; 26(8):1053-60. PubMed ID: 18383150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
